AGO TUMOR - AN OVERVIEW

In summary, during the last ten years by far the most impressive advantage has become reached in HER2/neu-overexpressing MBC. Introduction of bevacizumab for a VEGF-directed targeted remedy remains a problem on debate. A number of the novel therapeutics into the breast cancer armamentarium resulted in prolongation of survival for patients with MBC.